Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis

This study was undertaken to compare the effects of alendronate and risedronate on bone mineral density (BMD) and bone turnover markers (BTMs) in late postmenopausal women with osteoporosis. Thirty women older than 60 y of age were randomly assigned to receive alendronate 10 mg (n=16) or risedronate...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2006-11, Vol.23 (6), p.842-853
Main Authors: Atmaca, Aysegul, Gedik, Olcay
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Aged
Aged, 80 and over
Alendronate - therapeutic use
Biomarkers - blood
Bone Density - drug effects
Bone Density Conservation Agents - therapeutic use
Etidronic Acid - analogs & derivatives
Etidronic Acid - therapeutic use
Female
Femur Neck - diagnostic imaging
Health technology assessment
Humans
Lumbar Vertebrae - diagnostic imaging
Middle Aged
Osteoporosis, Postmenopausal - blood
Osteoporosis, Postmenopausal - drug therapy
Postmenopause
Prospective Studies
Radius - diagnostic imaging
Risedronate Sodium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was undertaken to compare the effects of alendronate and risedronate on bone mineral density (BMD) and bone turnover markers (BTMs) in late postmenopausal women with osteoporosis. Thirty women older than 60 y of age were randomly assigned to receive alendronate 10 mg (n=16) or risedronate 5 mg (n=14) on a daily basis. The patients were followed every 3 mo for 12 mo. BMD measurements were taken at baseline and at the end of the study, and BTMs were measured at 3-mo intervals. By the end of the study, there were statistically significant increases in BMD in both groups at all sites at which they were measured (P
ISSN:0741-238X
1865-8652
DOI:10.1007/BF02850205